Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristof Egervari

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Cytopathology : Official Journal of the British Society for Clinical Cytology|July 11, 2024
Cytological features of ependymal and choroid plexus tumoursKristof Egervari, Ekkehard Hewer
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 27, 2008
Re: A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibilityKristof Egervari, Zoltan Szollosi, Zoltan Nemes
Pathology, Research and Practice|July 12, 2011
Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancerKristof Egervari, Csaba Kosa, Zoltan Szollosi
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|May 24, 2008
Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization studyKristof Egervari, Zoltan Szollosi, Zoltan Nemes
Pathology, Research and Practice|February 13, 2007
Tissue microarray technology in breast cancer HER2 diagnosticsKristof Egervari, Zoltan Szollosi, Zoltan Nemes
American Journal of Clinical Pathology|February 18, 2006
Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practiceKristof Egervari, Zoltan Szollosi, Zoltan Nemes, et al.
Journal of Clinical Pathology|May 30, 2006
Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areasZoltan Szollosi, Beata Scholtz, Kristof Egervari, et al.
The Journal of Pathology|May 28, 2005
Re: Lottner et al. simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005; 205: 577-584Zoltan Szollosi, Kristof Egervari, Zoltan Nemes, et al.
Pathology, Research and Practice|July 29, 2005
Histiocyte-like cells expressing factor XIIIa do not belong to the neoplastic cell population in malignant fibrous histiocytomaZoltan Szollosi, Tamas Nemeth, Kristof Egervari, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 23, 2008
An alternative and reliable real-time quantitative PCR method to determine HER2/neu amplification in breast cancerKristof Egervari, Judit Toth, Zoltan Nemes, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Cytopathology : Official Journal of the British Society for Clinical Cytology|July 11, 2024
Cytological features of ependymal and choroid plexus tumoursKristof Egervari, Ekkehard Hewer
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 27, 2008
Re: A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibilityKristof Egervari, Zoltan Szollosi, Zoltan Nemes
Pathology, Research and Practice|July 12, 2011
Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancerKristof Egervari, Csaba Kosa, Zoltan Szollosi
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|May 24, 2008
Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization studyKristof Egervari, Zoltan Szollosi, Zoltan Nemes
Pathology, Research and Practice|February 13, 2007
Tissue microarray technology in breast cancer HER2 diagnosticsKristof Egervari, Zoltan Szollosi, Zoltan Nemes
American Journal of Clinical Pathology|February 18, 2006
Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practiceKristof Egervari, Zoltan Szollosi, Zoltan Nemes, et al.
Journal of Clinical Pathology|May 30, 2006
Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areasZoltan Szollosi, Beata Scholtz, Kristof Egervari, et al.
The Journal of Pathology|May 28, 2005
Re: Lottner et al. simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005; 205: 577-584Zoltan Szollosi, Kristof Egervari, Zoltan Nemes, et al.
Pathology, Research and Practice|July 29, 2005
Histiocyte-like cells expressing factor XIIIa do not belong to the neoplastic cell population in malignant fibrous histiocytomaZoltan Szollosi, Tamas Nemeth, Kristof Egervari, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 23, 2008
An alternative and reliable real-time quantitative PCR method to determine HER2/neu amplification in breast cancerKristof Egervari, Judit Toth, Zoltan Nemes, et al.
Pageof 6